CD22 CAR T-Cell Therapy for B-Cell Cancers
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol requires a washout period (time without taking certain medications) of at least 2 weeks or 5 half-lives, whichever is shorter, for most prior systemic therapies before starting the trial. However, some medications like hydroxyurea and certain maintenance chemotherapies have specific guidelines, so it's best to discuss your current medications with the trial team.
What data supports the effectiveness of the CD22 CAR T-Cell treatment for B-Cell cancers?
Research shows that CD22 CAR T-Cell treatment has high remission rates in certain B-cell cancers, like acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL), with complete response rates of 68% in ALL and 64% in NHL. This treatment is especially promising for patients who did not respond to or relapsed after CD19 CAR T-Cell therapy.12345
Is CD22 CAR T-cell therapy safe for humans?
CD22 CAR T-cell therapy has been studied in early phase trials for B-cell cancers like acute lymphocytic leukemia and non-Hodgkin's lymphoma. While most patients experienced some level of cytokine release syndrome (CRS, a reaction where the immune system becomes overly active), severe cases were rare. Neurotoxicity (problems with the nervous system) was also uncommon, suggesting that the therapy is generally safe, though more research is needed for long-term safety outcomes.12467
How is CD22 CAR T-cell therapy different from other treatments for B-cell cancers?
CD22 CAR T-cell therapy is unique because it targets the CD22 antigen on B-cells, offering an alternative for patients who do not respond to or relapse after CD19-targeted therapies. This approach helps address the issue of antigen loss, which can occur with CD19 therapies, and provides a new option for treating B-cell cancers.12458
What is the purpose of this trial?
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Research Team
Matthew Frank, PhD, MD
Principal Investigator
Stanford University
Eligibility Criteria
Adults over 18 with certain B-cell blood cancers that have come back or didn't respond to treatment. They must be able to consent, not pregnant, willing to use birth control, and meet specific health criteria like a minimum number of white blood cells and proper organ function. Can't join if they're pregnant/breastfeeding, have other cancers within 3 years, severe infections needing IV drugs, significant heart issues in the past year or conditions affecting study participation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion
Participants undergo lymphodepletion with Fludarabine and Cyclophosphamide prior to CD22 CAR T cell infusion
Treatment
Participants receive CD22 CAR T cell infusion at varying dose levels to determine MTD/RP2D
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CD22 CAR
- Cyclophosphamide
- Fludarabine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
The Leukemia and Lymphoma Society
Collaborator
American Society of Hematology
Collaborator
National Cancer Institute (NCI)
Collaborator